191 related articles for article (PubMed ID: 9493123)
1. Candesartan cilexetil reduces chronic renal allograft injury in Fisher-->Lewis rats.
Mackenzie HS; Ziai F; Nagano H; Azuma H; Troy JL; Rennke HG; Tilney NL; Brenner BM
J Hypertens Suppl; 1997 Dec; 15(6):S21-5. PubMed ID: 9493123
[TBL] [Abstract][Full Text] [Related]
2. Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats.
Noda M; Fukuda R; Matsuo T; Ohta M; Nagano H; Imura Y; Nishikawa K; Shibouta Y
Kidney Int Suppl; 1997 Dec; 63():S136-9. PubMed ID: 9407442
[TBL] [Abstract][Full Text] [Related]
3. Effects of candesartan cilexetil on oxidative state and renal function in 5/6 nephrectomized rats.
Sugimoto K; Tsuruoka S; Matsushita K; Fujimura A
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S63-70; discussion S81. PubMed ID: 10076923
[TBL] [Abstract][Full Text] [Related]
4. Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure.
Noda M; Matsuo T; Fukuda R; Ohta M; Nagano H; Shibouta Y; Naka T; Nishikawa K; Imura Y
Kidney Int; 1999 Sep; 56(3):898-909. PubMed ID: 10469358
[TBL] [Abstract][Full Text] [Related]
5. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
Fridman K; Andersson OK; Wysocki M; Friberg P; Sunzel M
Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
[TBL] [Abstract][Full Text] [Related]
6. Use of candesartan cilexetil decreases proteinuria in renal transplant patients with chronic allograft dysfunction.
Omoto K; Tanabe K; Tokumoto T; Shimmura H; Ishida H; Toma H
Transplantation; 2003 Oct; 76(8):1170-4. PubMed ID: 14578748
[TBL] [Abstract][Full Text] [Related]
7. Candesartan cilexetil protects against loss of autoregulatory efficiency in angiotensin II-infused rats.
Inscho EW; Imig JD; Deichmann PC; Cook AK
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S178-83. PubMed ID: 9892160
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin type 1 and type 2 receptor blockade in chronic allograft nephropathy.
Lutz J; Risch K; Liu S; Antus B; Schmaderer C; Roos M; Ouyang N; Lehmann M; Heemann U
Kidney Int; 2006 Sep; 70(6):1080-8. PubMed ID: 16850018
[TBL] [Abstract][Full Text] [Related]
9. [Candesartan cilexetil: pharmacological properties and protective effects against organ damage of a novel nonpeptide angiotensin II-receptor antagonist].
Inada Y; Naka T
Nihon Yakurigaku Zasshi; 2000 Mar; 115(3):151-60. PubMed ID: 10876800
[TBL] [Abstract][Full Text] [Related]
10. Renal allograft protection with losartan in Fisher-->Lewis rats: hemodynamics, macrophages, and cytokines.
Ziai F; Nagano H; Kusaka M; Coito AJ; Troy JL; Nadeau KC; Rennke HG; Tilney NL; Brenner BM; MacKenzie HS
Kidney Int; 2000 Jun; 57(6):2618-25. PubMed ID: 10844632
[TBL] [Abstract][Full Text] [Related]
11. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
Inada Y; Ojima M; Kanagawa R; Misumi Y; Nishikawa K; Naka T
J Hum Hypertens; 1999 Jan; 13 Suppl 1():S75-80. PubMed ID: 10076925
[TBL] [Abstract][Full Text] [Related]
12. Persistent cardiovascular effects of chronic renin-angiotensin system inhibition following withdrawal in adult spontaneously hypertensive rats.
Paull JR; Widdop RE
J Hypertens; 2001 Aug; 19(8):1393-402. PubMed ID: 11518847
[TBL] [Abstract][Full Text] [Related]
13. Effects of acute AT1 receptor blockade by candesartan on arterial pressure and renal function in rats.
Cervenka L; Wang CT; Navar LG
Am J Physiol; 1998 May; 274(5):F940-5. PubMed ID: 9612332
[TBL] [Abstract][Full Text] [Related]
14. In vivo inhibition of angiotensin receptors in the rat kidney by candesartan cilexetil: a comparison with losartan.
Fabiani ME; Dinh DT; Nassis L; Casley DJ; Johnston CI
Am J Hypertens; 2000 Sep; 13(9):1005-13. PubMed ID: 10981551
[TBL] [Abstract][Full Text] [Related]
15. Candesartan cilexetil reduces graft arteriosclerosis in aortic transplantation model in rat.
Zezina L; Larsson E; Fellström B
Transpl Immunol; 2001 Feb; 8(4):245-51. PubMed ID: 11316067
[TBL] [Abstract][Full Text] [Related]
16. Renal mass as a determinant of late allograft outcome: insights from experimental studies in rats.
Mackenzie HS; Azuma H; Rennke HG; Tilney NL; Brenner BM
Kidney Int Suppl; 1995 Dec; 52():S38-42. PubMed ID: 8587281
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.
Azizi M; Chatellier G; Guyene TT; Ménard J
J Hypertens; 1999 Apr; 17(4):561-8. PubMed ID: 10404959
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the antihypertensive effects of the new angiotensin II (AT1) receptor antagonist candesartan cilexetil (TCV-116) and the angiotensin converting enzyme inhibitor enalapril in rats.
Wada T; Inada Y; Ojima M; Sanada T; Shibouta Y; Nishikawa K
Hypertens Res; 1996 Jun; 19(2):75-81. PubMed ID: 10968199
[TBL] [Abstract][Full Text] [Related]
19. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET.
Philipp T; Martinez F; Geiger H; Moulin B; Mourad G; Schmieder R; Lièvre M; Heemann U; Legendre C
Nephrol Dial Transplant; 2010 Mar; 25(3):967-76. PubMed ID: 19887503
[TBL] [Abstract][Full Text] [Related]
20. The angiotensin receptor antagonist, irbesartan, reduces renal injury in experimental chronic renal failure.
Ziai F; Ots M; Provoost AP; Troy JL; Rennke HG; Brenner BM; Mackenzie HS
Kidney Int Suppl; 1996 Dec; 57():S132-6. PubMed ID: 8941934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
